Prevalence of Immunoglobulin G (IgG) Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Evaluation of a Rapid MEDsan IgG Test in Children Seeking Medical Care

Klara M Posfay-Barbe; Diego O Andrey; Julien Virzi; Patrick Cohen; Fiona Pigny; Ana R Goncalves; Selina Pinosch; Laurence Lacroix; Silvia Stringhini; Laurent Kaiser; Nicolas Vuilleumier; Arnaud G L'Huillier

doi:10.1093/cid/ciaa1702

Prevalence of Immunoglobulin G (IgG) Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Evaluation of a Rapid MEDsan IgG Test in Children Seeking Medical Care

Clin Infect Dis. 2021 Apr 8;72(7):e192-e195. doi: 10.1093/cid/ciaa1702.

Authors

Affiliations

¹ Department of Woman, Child, and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
² Department of Diagnostics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
³ Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
⁴ Department of Primary Care Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Abstract

In 208 children seeking medical care, the seropositivity rate of anti-SARS-CoV-2 IgG antibodies was 8.7%, suggesting an infection rate similar to that observed in adults but >100-fold the incidence of RT-PCR-confirmed pediatric cases. Compared with the gold-standard combined ELISA + immunofluorescence, the MEDsan IgG rapid diagnostic test performed accurately.

Keywords: COVID-19; antibody; pediatrics; rapid diagnostic test; seroprevalence.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Viral
COVID-19*
Child
Humans
Immunoglobulin G
Immunoglobulin M
Prevalence
SARS-CoV-2*

Substances

Antibodies, Viral
Immunoglobulin G
Immunoglobulin M